Trial · NCT04950127
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part A: Mean Change From Baseline in Monthly Itch Scores Over 24 Weeks Using Numerical Rating Scale (NRS) | Part A: Linerixibat 40 Milligrams (mg) | -2.86 | 95% Confidence Interval -3.23 to -2.50 | Scores on a scale | |
| Part A: Mean Change From Baseline in Monthly Itch Scores Over 24 Weeks Using Numerical Rating Scale (NRS) | Part A: Placebo | -2.15 | 95% Confidence Interval -2.51 to -1.78 | Scores on a scale | |
| Part A: Mean Change From Baseline in Weekly Itch Score at Week 2 Using NRS | Part A: Linerixibat 40 Milligrams (mg) | -1.78 | 95% Confidence Interval -2.08 to -1.48 | Scores on a scale | |
| Part A: Mean Change From Baseline in Weekly Itch Score at Week 2 Using NRS | Part A: Placebo | -1.07 | 95% Confidence Interval -1.37 to -0.77 | Scores on a scale | |
| Part A: Mean Change From Baseline in Monthly Sleep Score Over 24 Weeks Using NRS | Part A: Linerixibat 40 Milligrams (mg) | -2.77 | 95% Confidence Interval -3.15 to -2.38 | Scores on a scale | |
| Part A: Mean Change From Baseline in Monthly Sleep Score Over 24 Weeks Using NRS | Part A: Placebo | -2.24 | 95% Confidence Interval -2.62 to -1.86 | Scores on a scale | |
| Part A: Percentage of Responders Defined as Achieving More Than or Equal to (>=) 2-point Reduction From Baseline in the Monthly Itch Score at Week 24 | Part A: Linerixibat 40 Milligrams (mg) | 68.0 | Percentage of participants | ||
| Part A: Percentage of Responders Defined as Achieving More Than or Equal to (>=) 2-point Reduction From Baseline in the Monthly Itch Score at Week 24 | Part A: Placebo | 64.0 | Percentage of participants | ||
| Part A: Percentage of Responders Achieving >=3-point Reduction From Baseline in the Monthly Itch Score at Week 24 | Part A: Linerixibat 40 Milligrams (mg) | 56.0 | Percentage of participants | ||
| Part A: Percentage of Responders Achieving >=3-point Reduction From Baseline in the Monthly Itch Score at Week 24 | Part A: Placebo | 43.0 | Percentage of participants | ||
| Part A: Percentage of Responders as Achieving a >=4-point Reduction From Baseline in the Monthly Itch Score at Week 24 | Part A: Linerixibat 40 Milligrams (mg) | 41.0 | Percentage of participants | ||
| Part A: Percentage of Responders as Achieving a >=4-point Reduction From Baseline in the Monthly Itch Score at Week 24 | Part A: Placebo | 29.0 | Percentage of participants | ||
| Part A: Mean Change From Baseline in Primary Biliary Cholangitis-40 (PBC-40) Domain Scores at Week 24 | Part A: Linerixibat 40 Milligrams (mg) | Cognitive (score range: 6 to 30) | -0.71 | 95% Confidence Interval -1.60 to 0.18 | Scores on a scale |
| Part A: Mean Change From Baseline in Primary Biliary Cholangitis-40 (PBC-40) Domain Scores at Week 24 | Part A: Placebo | Cognitive (score range: 6 to 30) | -1.47 | 95% Confidence Interval -2.36 to -0.58 | Scores on a scale |
| Part A: Mean Change From Baseline in Primary Biliary Cholangitis-40 (PBC-40) Domain Scores at Week 24 | Part A: Linerixibat 40 Milligrams (mg) | Emotional (score range: 3 to 15) | -1.07 | 95% Confidence Interval -1.57 to -0.57 | Scores on a scale |
| Part A: Mean Change From Baseline in Primary Biliary Cholangitis-40 (PBC-40) Domain Scores at Week 24 | Part A: Placebo | Emotional (score range: 3 to 15) | -1.34 | 95% Confidence Interval -1.83 to -0.84 | Scores on a scale |
| Part A: Mean Change From Baseline in Primary Biliary Cholangitis-40 (PBC-40) Domain Scores at Week 24 | Part A: Linerixibat 40 Milligrams (mg) | Fatigue (score range: 11 to 55) | -2.94 | 95% Confidence Interval -4.63 to -1.26 | Scores on a scale |
| Part A: Mean Change From Baseline in Primary Biliary Cholangitis-40 (PBC-40) Domain Scores at Week 24 | Part A: Placebo | Fatigue (score range: 11 to 55) | -4.54 | 95% Confidence Interval -6.21 to -2.86 | Scores on a scale |
| Part A: Mean Change From Baseline in Primary Biliary Cholangitis-40 (PBC-40) Domain Scores at Week 24 | Part A: Linerixibat 40 Milligrams (mg) | Itch (score range: 0 to 15) | -3.47 | 95% Confidence Interval -4.08 to -2.86 | Scores on a scale |
| Part A: Mean Change From Baseline in Primary Biliary Cholangitis-40 (PBC-40) Domain Scores at Week 24 | Part A: Placebo | Itch (score range: 0 to 15) | -2.89 | 95% Confidence Interval -3.50 to -2.28 | Scores on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04950127/results